Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference
Protalix BioTherapeutics (NYSE American:PLX), a biopharmaceutical company specializing in recombinant therapeutic proteins using its proprietary ProCellEx® plant cell-based expression system, has announced its participation in the 2025 BIO CEO & Investor Conference.
The event will take place on February 10-11, 2025, at the New York Marriott Marquis. Company management will deliver a corporate presentation on Tuesday, February 11, 2025, at 10:15 AM EST in the Royale Room. The presentation will subsequently be made available in the Investors section of the company's website under the Event Calendar tab.
Management will also be available for one-on-one meetings with registered investors and conference attendees. Interested parties are encouraged to schedule meetings through the BIO CEO attendee portal.
Protalix BioTherapeutics (NYSE American:PLX), una compagnia biofarmaceutica specializzata in proteine terapeutiche ricombinanti utilizzando il suo sistema proprietario di espressione a base di cellule vegetali ProCellEx®, ha annunciato la sua partecipazione alla 2025 BIO CEO & Investor Conference.
L'evento si terrà il 10-11 febbraio 2025, presso il New York Marriott Marquis. La direzione aziendale offrirà una presentazione aziendale martedì 11 febbraio 2025, alle 10:15 AM EST nella Royale Room. La presentazione sarà successivamente disponibile nella sezione Investitori del sito web dell'azienda, sotto la scheda Calendario degli eventi.
La direzione sarà inoltre disponibile per incontri individuali con investitori registrati e partecipanti alla conferenza. Le parti interessate sono invitate a pianificare incontri tramite il portale per partecipanti BIO CEO.
Protalix BioTherapeutics (NYSE American:PLX), una empresa biofarmacéutica especializada en proteínas terapéuticas recombinantes que utiliza su sistema de expresión basado en células vegetales ProCellEx® de forma propietaria, ha anunciado su participación en la 2025 BIO CEO & Investor Conference.
El evento se llevará a cabo el 10-11 de febrero de 2025, en el New York Marriott Marquis. La dirección de la empresa realizará una presentación corporativa el martes 11 de febrero de 2025, a las 10:15 AM EST en la Royale Room. La presentación estará disponible posteriormente en la sección de Inversores del sitio web de la empresa, bajo la pestaña Calendario de eventos.
La dirección también estará disponible para reuniones individuales con inversores registrados y asistentes a la conferencia. Se anima a las partes interesadas a programar reuniones a través del portal de asistentes del BIO CEO.
Protalix BioTherapeutics (NYSE American:PLX)는 자사의 독점적인 식물세포 기반 발현 시스템인 ProCellEx®를 사용하여 재조합 치료 단백질을 전문으로 하는 생명공학 회사로, 2025 BIO CEO & Investor Conference에 참가한다고 발표했습니다.
이 행사는 2025년 2월 10일-11일에 뉴욕 매리엇 마르키스에서 열립니다. 회사 경영진은 2025년 2월 11일 화요일 오전 10:15 EST에 로얄룸에서 기업 발표를 진행할 것입니다. 발표는 이후 회사 웹사이트의 투자자 섹션 이벤트 캘린더 탭에서 확인할 수 있습니다.
경영진은 등록된 투자자 및 컨퍼런스 참석자와의 일대일 미팅에도 참석할 예정입니다. 관심 있는 분들은 BIO CEO 참석자 포털을 통해 미팅 일정을 잡으실 수 있습니다.
Protalix BioTherapeutics (NYSE American:PLX), une société biopharmaceutique spécialisée dans les protéines thérapeutiques recombinantes en utilisant son système d'expression à base de cellules végétales ProCellEx®, a annoncé sa participation à la 2025 BIO CEO & Investor Conference.
L'événement se déroulera les 10-11 février 2025, au New York Marriott Marquis. La direction de l'entreprise présentera une présentation d'entreprise le mardi 11 février 2025, à 10h15 EST dans la salle Royale. La présentation sera ensuite disponible dans la section Investisseurs du site Web de l'entreprise, sous l'onglet Calendrier des événements.
La direction sera également disponible pour des réunions individuelles avec des investisseurs inscrits et des participants à la conférence. Les parties intéressées sont encouragées à planifier des réunions via le portail des participants BIO CEO.
Protalix BioTherapeutics (NYSE American:PLX), ein biopharmazeutisches Unternehmen, das sich auf rekombinante Therapeutika mit seinem proprietären auf Pflanzenzellen basierenden ProCellEx®-Expressionssystem spezialisiert hat, hat seine Teilnahme an der 2025 BIO CEO & Investor Conference bekannt gegeben.
Die Veranstaltung findet am 10.-11. Februar 2025 im New York Marriott Marquis statt. Das Management des Unternehmens wird am Dienstag, den 11. Februar 2025, um 10:15 Uhr EST im Royale Room eine Unternehmenspräsentation halten. Die Präsentation wird anschließend im Anlegerbereich der Unternehmenswebsite unter dem Reiter Veranstaltungskalender verfügbar sein.
Das Management wird auch für persönliche Gespräche mit registrierten Investoren und Konferenzteilnehmern zur Verfügung stehen. Interessierte Parteien werden ermutigt, Meetings über das BIO CEO Teilnehmerportal zu planen.
- None.
- None.
Corporate presentation scheduled for Tuesday, February 11, 2025 at 10:15 AM EST
CARMIEL,
Management is scheduled to give a corporate overview at the BIO CEO & Investor Conference on Tuesday, February 11, 2025 at 10:15 AM EST at the Royale Room and will be available to participate in one-on-one partnering meetings with registered investors and other conference attendees. Following the presentation, a copy will be available under the Event Calendar tab in the Investors section of the Company's website.
Conference attendees that would like to schedule a meeting with the Company's management are encouraged to register through the BIO CEO attendee portal.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in
Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX–119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others.
Investor Contact
Mike Moyer, Managing Director
LifeSci Advisors
617 308 4306
mmoyer@lifesciadvisors.com
Logo - https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-participate-in-the-2025-bio-ceo--investor-conference-302367286.html
SOURCE Protalix BioTherapeutics, Inc.
FAQ
When is Protalix BioTherapeutics (PLX) presenting at the 2025 BIO CEO Conference?
Where can investors access PLX's 2025 BIO CEO Conference presentation materials?
How can investors schedule one-on-one meetings with PLX management at the BIO CEO Conference?
What is the location of the 2025 BIO CEO Conference where PLX will present?
What dates will the 2025 BIO CEO Conference featuring PLX take place?
